Citius Oncology, Inc. CTOR
0.58 USD +0.03 (+5.04%)
Nov 4, 2026, 11:26 AM EST
0.5651 Day range 0.5947
0.491 52-week range 1.83
- YTD
- -42.23%
- 1 year
- -63.20%
Financial health
Altman Z-Score
-2.32 Distress zone
Bankruptcy-risk model: below 1.81 distress, above 2.99 safe.
Piotroski F-Score
3 / 9 Weak
Nine pass/fail tests of profitability, leverage and efficiency.
FMP rating
C2 / 5 overall
- DCF 2
- Return on Equity 1
- Return on Assets 1
- Debt / Equity 2
- P/E 1
- P/B 4
Valuation
P/E -6.0×
FY 2022 5y median -33.1× FY 2025
P/S 0.0×
FY 2022 5y median 0.0× FY 2025
P/B 3.3×
FY 2022 5y median 15.9× FY 2025
P/FCF -27.1×
FY 2022 5y median -864× FY 2025
EV/EBITDA -6.3×
FY 2022 5y median -5.7× FY 2025
EV/Sales 0.0×
FY 2022 5y median 0.0× FY 2025
FCF Yield -3.7%
FY 2022 5y median -0.0% FY 2025
Profitability
Gross Margin 0.0%
FY 2022 5y median 0.0% FY 2025
Operating Margin 0.0%
FY 2022 5y median 0.0% FY 2025
Net Margin 0.0%
FY 2022 5y median 0.0% FY 2025
ROE -55.2%
FY 2022 5y median -47.8% FY 2025
ROIC -45.7%
FY 2022 5y median -42.6% FY 2025
ROA -24.5%
FY 2022 5y median -25.3% FY 2025
Growth (YoY)
Revenue 0.0%
FY 2022 FY 2025
Operating Income -14.3%
FY 2022 FY 2025
EPS (diluted) -13.3%
FY 2022 FY 2025
Free Cash Flow -4446.7%
FY 2022 FY 2025
Financial Health
Current Ratio 0.6×
FY 2022 5y median 0.4× FY 2025
Quick Ratio 0.1×
FY 2022 5y median 0.2× FY 2025
Debt / Equity 0.1×
FY 2022 5y median 0.0× FY 2025
Net Debt / EBITDA 0.0×
FY 2022 5y median 0.0× FY 2025
Interest Coverage -108×
FY 2022 5y median 0.0× FY 2025
Dividends
Dividend Yield 0.0%
FY 2022 5y median 0.0% FY 2025
Payout Ratio 0.0%
FY 2022 5y median 0.0% FY 2025
Annual · latest fiscal year ends 2025-09-30